The DEA Just Cracked the Door. Smart Money Is Through It.

For more than half a century, cannabis investors have been trading a sector held hostage by a single line in the Controlled Substances Act. Marijuana was Schedule I — lumped in with heroin, declared to have no accepted medical use — and that classification did the quiet, brutal work of keeping the entire U.S. plant-touching industry off national exchanges, away from real banking, and starved of the institutional capital that flows freely to every other consumer category in America.

In late April, the DEA blinked.

The agency issued a final order moving two categories of marijuana — FDA-approved marijuana drug products and marijuana covered by a qualifying state medical license — onto Schedule III. It is a narrow order. But the more important move came attached to it: the DEA scheduled an administrative hearing for June 29 to take evidence on whether to reschedule marijuana more broadly to Schedule III. That hearing is the real catalyst, and the market knows it.

What the April order actually does

Let’s be precise, because precision is where most cannabis coverage falls apart. The April rule does not legalize anything. It does not create an open market. It moves a limited slice of the plant — FDA-approved products and state-licensed medical marijuana — into Schedule III, where substances like ketamine and Tylenol with codeine live: accepted medical use, lower abuse potential, dispensable under controlled conditions. Everything outside that narrow lane stays Schedule I. Synthetic THC stays Schedule I. Hemp remains outside the CSA’s definition of marijuana entirely, untouched by the rule.

So the adult-use business — the recreational dispensaries and production that make up the overwhelming majority of state-legal cannabis revenue — is not what got rescheduled. That distinction matters enormously when you start thinking about who can actually list, and when.

Why the listing math changes

A national exchange listing requires that an issuer’s current and planned activities not violate federal law. That single requirement is the wall the entire U.S. cannabis sector has been staring at. Schedule I status meant a plant-touching operator was, by definition, federally illegal, and Nasdaq and the NYSE were never going to invite that to the party.

Full rescheduling to Schedule III would begin to dismantle that wall — at least for companies whose operations are directed at Schedule III-compliant activities. But here is the catch the bulls keep glossing over: an exchange may only be willing to list a company that can show its business is confined to compliant activity. A pure state-licensed medical operator has a story to tell. A multistate operator with the bulk of its revenue tied to adult-use recreational sales has a much harder conversation, even in a post-rescheduling world.

And the exchange is only the first gatekeeper. A real listing needs underwriters, placement agents, auditors, transfer agents, custodians, clearing agencies, and broker-dealers — each carrying its own regulator, its own risk committee, and its own appetite for cannabis exposure. Rescheduling changes the legal classification. It does not, by itself, change the risk tolerance of every institution in the plumbing. That shift happens separately, and usually slower than the headline suggests.

The rumor

Now to the chatter. Circulating around the sector this month is an unsubstantiated rumor — and it should be treated as exactly that, unconfirmed and unsourced — that federal guidance addressing both the tax treatment of cannabis operators and a clearer uplisting pathway could land within the next few weeks. We have not verified it, no agency has signaled it, and readers should weight it accordingly. It is precisely the kind of unsourced talk that tends to swirl ahead of a known catalyst date, and it is worth naming only because the calendar gives it a sliver of plausibility: the June 29 hearing is real, and regulators have a documented habit of issuing interpretive guidance in the wake of scheduling moves.

There is precedent for the shape of it, if not the timing. After the 2014 reforms, FinCEN issued guidance that became the reference point for how financial institutions handled cannabis clients for the better part of a decade. A move on Schedule III could plausibly prompt new guidance from Treasury, the IRS, or FinCEN clarifying enforcement priorities and — the piece operators care about most — the fate of Section 280E, the tax provision that has bled plant-touching companies dry by denying them ordinary business deductions. If 280E relief follows rescheduling, the earnings impact for profitable operators would be immediate and large. But again: the timeline in the rumor is unverified. Trade the hearing, not the whisper.

What it means for the names

Start with MSOS, the AdvisorShares Pure US Cannabis ETF, which functions as the sector’s heartbeat and the cleanest way to express a view on the entire complex. It moves on exactly this kind of regulatory headline, and it carries the basket risk and reward of the multistate operators inside it. If you believe rescheduling momentum is real and underpriced, MSOS is the blunt instrument. If you think the market is front-running a narrow rule as though it were full legalization, it is also the cleanest thing to fade.

Trulieve (TCNNF) enters this window as one of the most operationally profitable and cash-generative operators in the space, with a deep concentration in medical-heavy markets — which, under the logic of the April rule, is the profile that travels best toward a compliant-activity listing story. Green Thumb (GTBIF) brings consistent profitability and disciplined capital management, the kind of financial hygiene that matters intensely once you remember that a listing requires PCAOB audits, clean cap tables, and public-company controls. Operators that already run like public companies are the ones positioned to move first when a window opens.

Curaleaf (CURLF) is the scale play — one of the largest footprints in the industry, with the revenue base and brand reach that make it a default institutional proxy for U.S. cannabis, balanced against the leverage and adult-use exposure that complicate the cleanest version of the listing narrative. The recurring theme across all four: rescheduling rewards the prepared. The operators with audited financials, simplified capital structures, and a defensible compliant-activity story are the ones that capitalize when the door opens. The rest react.

The honest bottom line

The April rule is a real step and the June 29 hearing is a real catalyst — but neither is the finish line, and the gap between “rescheduled” and “freely listed and banked” is wider than the tape wants to price. The capital-markets unlock requires the exchanges, the banks, the auditors, and the regulators to move in rough sequence, and they rarely move on the same clock. The smart positioning is not to chase a rumor about guidance in the next few weeks. It is to own the names that are built to act — not react — if and when the window actually opens, and to size for the reality that windows in this sector have a long history of opening more slowly than anyone hoped.

Watch June 29. Treat the rest as noise until it isn’t.

___________

Disclosure: The author holds options positions in MSOS, $MSOS Call options, $MSOX, $TCNNF, $CRLBF, $TSNDF. This article is for informational purposes only and does not constitute investment, legal, or tax advice. StockAlpha.ai is not a registered investment adviser or broker-dealer. Do your own research.